Prognostic significance of p34(cdc2) cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer

American Journal of Clinical Pathology

Volumn 112, Issue 4, 1999, Pages 459-469

  Depowski, Peter L ^a   Brien, Thomas P ^a   Sheehan, Christine E ^a   Stylos, Scott ^b   Johnson, Rebecca L ^b   Ross, Jeffrey S ^a,c  

^a ALBANY MEDICAL CENTER   (United States)

^b BERKSHIRE MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

FISH; Fluorescence in situ hybridization; Immunohistochemistry; Proliferation; Survival

Indexed keywords

CYCLIN DEPENDENT KINASE; KI 67 ANTIGEN; PROTEIN KINASE; CELL NUCLEUS ANTIGEN; CYCLIN DEPENDENT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NUCLEAR PROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; BREAST TUMOR; CHEMISTRY; GENE AMPLIFICATION; GENETICS; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; LYMPH NODES; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0033238166     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/112.4.459     Document Type: Article

References (61)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5-27.
2. Page DL. Prognosis and breast cancer: recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991;15:334-349.
3. Porter-Jordan K, Lippman ME. Overview of the biologic markers in breast cancer. Hematol Oncol Clin N Am. 1994;8:73-100.
4. Popescu NC, King CR, Kraus MH. Localization of the erbB-2 gene on normal and rearranged chromosomes 17 to hands q12-21.32. Genomics. 1989;4:362-366.
5. Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989;16:148-155.
6. Slamon DJ, Clark CM, Wong SO, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
8. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7:1120-1128.
9. O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between c-erbB-2 overexpression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991;63:444-446.
10. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.
11. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol. 1992;10:1044-1048.
12. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic factors, histologic natures, and prognosis. Cancer. 1995;75:1320-1326.
13. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991;51:944-948.
14. Ali IU, Campbell G, Lidereau R, et al. Lack of evidence for the prognostic significance of c-erb-B2 amplification in human breast carcinoma. Oncol Res.1988;3:139-146.
15. Kay EW, Barry Walsh CJ, Cassidy M, et al. C-erb-B2 immunostaining: problems with interpretation. J Clin Pathol. 1994;47:816-822.
16. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
17. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescent in-situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
18. Persons DL, Borrelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in-situ hybridization. Mod Pathol. 1997;10:720-727.
19. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
20. PSK-J3/CDK4) for mammalian D type G1 cyclins. Cell. 1992;71:323-334.
21. Sherr CJ, Mammalian G1 cyclins. Cell. 1993;73:1059-1065.
22. Dunphy WG. The decision to enter mitoses: trends. Cell Biol. 1994;4:202-207.
23. cdc2 in cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity. J Pathol. 1996;178:422-428.
24. cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer. 1993;53:36-41.
25. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Nat Acad Sci U S A. 1993;90:1112-1116.
26. cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer. 1997;80:754-763.
27. Kawamoto H, Koizumi Hi, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and CDC2 in non-malignant and malignant human breast lesions: immunocytochemical and quantitative image analysis. Am J Pathol. 1997;150:15-23.
28. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
29. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
30. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 1989;927-930.
31. Yonemura Y, Ooyama S, Sugiyama K, et al. Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer. 1990;65:1130-1134.
32. Simony J, Pujol JL, Radal M, et al. In-situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res. 1990;50:4382-4387.
33. Isola JJ, Helin HJ, Helle MJ, et al. Evaluation of cell proliferation in breast carcinoma: comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65:1180-1184.
34. Railo M, Lundin J, Haglund C, et al. Ki-67, p53, ER receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol. 1997;36:369-374.
35. Dettmar P, Harbeck N, Thomssen C, et al. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node negative breast cancer. Br J Cancer. 1997;75:1525-1533.
36. Pietilainen T, Lipponen P, Aaltomaa S, et al. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol. 1996;122:687-692.
37. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histologic grade in breast cancer: experience from a large study with long term follow up. Histopathology. 1991;194:403-410.
38. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741-748.
39. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node negative breast cancer: prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol 1992;10:599-605.
40. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
41. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
42. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody in patients with HER-2/neu overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-744.
43. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829-1838.
44. Smith KL, Robbins PD, Dawkins HJ, et al. c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in-situ hybridization. Hum Pathol. 1994;25:413-418.
45. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. HER-2/neu gene amplification status in prostate cancer by fluorescent in-situ hybridization. Hum Pathol. 1997;28:827-833.
46. Murphy DS, McHardy P, Coutts J, et al. Interphase cytogenetic analysis of erbB2 in topo II a co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in-situ. Int J Cancer. 1995;64:18-26.
47. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in-situ hybridization of prostate carcinoma. Cancer. 1997;79:2167-2170.
48. Saffari B, Jones LA, el-Naggar A, et al. Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival. Cancer Res. 1995;55:5693-5698.
49. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991;63:434-438.
50. Ro JS, el-Naggar A, Ro JY, et al. c-erbB-2 amplification in node-negative breast cancer. Cancer Res.1989;49:6941-6944.
51. Wright C, Angus B, Nicholson S, et al. Expression of c-erb-B2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.
52. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
53. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989;49:7147-7152.
54. Richner J, Gerber HA, Locher GW, et al. c-erbB-2 protein expression in node negative breast cancer. Ann Oncol. 1990;1:263-268.
55. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991;63:439-443.
56. cdc2 complex. Breast Cancer Res Treat. 1997;4:47-56.
57. Locker AP, Birrell K, Bell J A, et al. Ki-67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol. 1992;18:224-229.
58. Bouzubar N, Walker KJ, Griffiths K, et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989;59:943-947.
59. Pavelic ZP, Pavelic L, Lower EE, et al. c-myc, c-erb-B2 and Ki-67 expression in normal breast tissue and in invasive and non-invasive breast carcinoma. Cancer Res. 1992;52:2597-2602.
60. Gasparini G, Pozza F, Meli S, et al. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res. 1991;11:2015-2021.
61. Pierga JY, Leroyer A, Viehl P, et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat. 1996;37:57-64.